Abstract
Bisphosphonates, especially nitrogen-containing bisphosphonates (N-BPs), are widely used to block bone destruction in cancer patients with bone metastasis because they are effective inhibitors of osteoclast-mediated bone resorption. In addition to their antiresorptive effects, preclinical evidence strongly suggests that N-BPs have anticancer activity. Some of the activities associated with N-BPs are observed in human γδ T cells that straddle the interface of innate and adaptive immunity and have potent anti-tumour activity. This review examines the molecular and cellular mechanisms through which N-BPs stimulate the expansion and cytotoxic activity of human γδ T cells. In addition, we discuss the emerging clinical evidence that N-BPs have a role in cancer immunotherapy.
Keywords: Bisphosphonate, zoledronate, IPP, gamma delta T cell, immunotherapy, cancer, Cancer Immunotherapy, nitrogen-containing bisphosphonates (N-BPs), osteoclast-mediated bone resorption, sorptive effects, T cells, mevalonate path-way, isoprenoid lipids, farnesyl pyrophosphate synthase (FPPS), GTPases, monocytes, macrophages, endothelial, tumour cells, adaptive immunity, Innate immunity, macro-phages, antigen-targeted cytotoxic cells, histocompatibil-ity complex (MHC), farnesyl pyrophosphate (FPP), tumour antigen, phosphoantigens, cytokines, Tregs' activity, pa-midronate, risedronate, immunostimulatory properties, antigen-presenting cells, peripheral blood mononuclear cells (PBMC), putative antigen-presenting molecule, nonhuman antigen-presenting, cytolytic granules, anti-tumour activity, chronic myelogenous leukemic cells, autologous, kemia cells, allogeneic, zoledronate-treated, myeloid leukemia, CANCER IMMUNO-THERAPY, antigen-recognition properties, a synthetic phosphoantigen, pleiotropic pharmaceutical agents, tumor-hostile counterpart, goserelin, tamoxifen, anastrozole, endocrine-responsive, multichemotherapy, chemorefractory adrenocortical carcinoma
Current Pharmaceutical Design
Title: Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy
Volume: 16 Issue: 27
Author(s): P. Clezardin and M. Massaia
Affiliation:
Keywords: Bisphosphonate, zoledronate, IPP, gamma delta T cell, immunotherapy, cancer, Cancer Immunotherapy, nitrogen-containing bisphosphonates (N-BPs), osteoclast-mediated bone resorption, sorptive effects, T cells, mevalonate path-way, isoprenoid lipids, farnesyl pyrophosphate synthase (FPPS), GTPases, monocytes, macrophages, endothelial, tumour cells, adaptive immunity, Innate immunity, macro-phages, antigen-targeted cytotoxic cells, histocompatibil-ity complex (MHC), farnesyl pyrophosphate (FPP), tumour antigen, phosphoantigens, cytokines, Tregs' activity, pa-midronate, risedronate, immunostimulatory properties, antigen-presenting cells, peripheral blood mononuclear cells (PBMC), putative antigen-presenting molecule, nonhuman antigen-presenting, cytolytic granules, anti-tumour activity, chronic myelogenous leukemic cells, autologous, kemia cells, allogeneic, zoledronate-treated, myeloid leukemia, CANCER IMMUNO-THERAPY, antigen-recognition properties, a synthetic phosphoantigen, pleiotropic pharmaceutical agents, tumor-hostile counterpart, goserelin, tamoxifen, anastrozole, endocrine-responsive, multichemotherapy, chemorefractory adrenocortical carcinoma
Abstract: Bisphosphonates, especially nitrogen-containing bisphosphonates (N-BPs), are widely used to block bone destruction in cancer patients with bone metastasis because they are effective inhibitors of osteoclast-mediated bone resorption. In addition to their antiresorptive effects, preclinical evidence strongly suggests that N-BPs have anticancer activity. Some of the activities associated with N-BPs are observed in human γδ T cells that straddle the interface of innate and adaptive immunity and have potent anti-tumour activity. This review examines the molecular and cellular mechanisms through which N-BPs stimulate the expansion and cytotoxic activity of human γδ T cells. In addition, we discuss the emerging clinical evidence that N-BPs have a role in cancer immunotherapy.
Export Options
About this article
Cite this article as:
Clezardin P. and Massaia M., Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy, Current Pharmaceutical Design 2010; 16 (27) . https://dx.doi.org/10.2174/138161210793563545
DOI https://dx.doi.org/10.2174/138161210793563545 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current and Future Medical Therapy, and the Molecular Features of Adrenocortical Cancer
Recent Patents on Anti-Cancer Drug Discovery Glucocorticoid Measurements in Health and Disease - Metabolic Implications and the Potential of 24-h Urine Analyses
Mini-Reviews in Medicinal Chemistry Human Carbonyl Reductases
Current Drug Metabolism Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Glucocorticoids and Vascular Reactivity
Current Vascular Pharmacology Redox Environment and its Meaning for Breast Cancer Cells Fate
Current Cancer Drug Targets Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology A Point of View: The Need to Identify an Antigen in Psyconeuroimmunological Disorders
Current Pharmaceutical Design Impact of Early Life Stress on the Pathogenesis of Mental Disorders: Relation to Brain Oxidative Stress
Current Pharmaceutical Design Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Pharmacological Therapy of Cushings Syndrome: Drugs and Indications
Mini-Reviews in Medicinal Chemistry An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein
Current Cancer Drug Targets Nicotine, Body Weight and Potential Implications in the Treatment of Obesity
Current Topics in Medicinal Chemistry Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets Development of Mitotane Lipid Nanocarriers and Enantiomers: Two-in-One Solution to Efficiently Treat Adreno-Cortical Carcinoma
Current Medicinal Chemistry Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Current Metabolomic Methodologies & their Application to Thermal Stress
Current Metabolomics Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design